TY - JOUR
T1 - Identification of a superimmunoglobulin gene family member overexpressed in benign prostatic hyperplasia
AU - Wright, George L.
AU - Beckett, Mary Lou
AU - Newhall, Kathy R.
AU - Adam, Bao Ling
AU - Cazares, Lisa H.
AU - Cartwright, Suzanne L.
AU - Xiao, Zhen
AU - Gong, Lei
AU - Schellhammer, Paul F.
PY - 2000/2/15
Y1 - 2000/2/15
N2 - BACKGROUND. Benign prostate hyperplasia (BPH), a nonmalignant disease with an increasing rate of occurrence associated with advancing age, requires auxiliary markers to help identify its presence and distinguish its progression from prostate cancer. METHODS. Hybridoma technology was used to generate an antibody against a BPH antigen, which was subsequently characterized by Western blot analysis, sequence homology, and RT-PCR. RESULTS. A BPH-associated protein, designated P25/26, was identified that showed a strong sequence similarity with superimmunoglobulin family members, overexpressed in BPH, with lower expression observed in both normal and prostate cancer tissues. CONCLUSIONS. Further studies appear warranted to assess the role that this and other superimmunoglobulin family members may have in the pathogenesis of BPH, and to determine if these glycoproteins have any clinical utility in the differential diagnosis or therapeutic monitoring of BPH. (C) 2000 Wiley-Liss, Inc.
AB - BACKGROUND. Benign prostate hyperplasia (BPH), a nonmalignant disease with an increasing rate of occurrence associated with advancing age, requires auxiliary markers to help identify its presence and distinguish its progression from prostate cancer. METHODS. Hybridoma technology was used to generate an antibody against a BPH antigen, which was subsequently characterized by Western blot analysis, sequence homology, and RT-PCR. RESULTS. A BPH-associated protein, designated P25/26, was identified that showed a strong sequence similarity with superimmunoglobulin family members, overexpressed in BPH, with lower expression observed in both normal and prostate cancer tissues. CONCLUSIONS. Further studies appear warranted to assess the role that this and other superimmunoglobulin family members may have in the pathogenesis of BPH, and to determine if these glycoproteins have any clinical utility in the differential diagnosis or therapeutic monitoring of BPH. (C) 2000 Wiley-Liss, Inc.
KW - Benign prostate biomarkers
KW - Monoclonal antibody
KW - Prostate carcinoma
UR - http://www.scopus.com/inward/record.url?scp=0342680143&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0342680143&partnerID=8YFLogxK
U2 - 10.1002/(SICI)1097-0045(20000215)42:3<230::AID-PROS9>3.0.CO;2-J
DO - 10.1002/(SICI)1097-0045(20000215)42:3<230::AID-PROS9>3.0.CO;2-J
M3 - Article
C2 - 10639194
AN - SCOPUS:0342680143
SN - 0270-4137
VL - 42
SP - 230
EP - 238
JO - Prostate
JF - Prostate
IS - 3
ER -
